Axial spondyloarthritis and inflammatory bowel disease: association between disease activity and endothelial dysfunction markers
Open Access
- 8 July 2021
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 42 (2) , 273-277
Abstract
Objective: We aimed to assess patients with axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) for disease activity and serum markers of endothelial dysfunction. Methods: We studied 161 patients (123 males, 38 females) with axSpA: 153 with ankylosing spondylitis and 8 with non-radiographic axSpA, and 30 healthy controls (HC). We collected: age; sex; disease duration; extra-articular symptoms (IBD and acute anterior uveitis), comorbidities; human leukocyte antigen B27 status; and treatment. We measured serum interleukin (IL)-6, interleukin-18, IL-23, vascular endothelial growth factor (VEGF) epidermal growth factor (EGF), asymmetric dimethylarginine (ADMA), endothelin-1 (ET-1), and fetuin-A levels. Results: IBD was diagnosed in 19 (11.8%) patients with axSpA. Compared to patients with axSpA without IBD, those with IBD had higher serum C-reactive protein (CRP) level (p = 0.05), erythrocyte sedimentation rate (ESR) (p = 0.005), and serum ET-1 levels (p = 0.01). In patients with axSpA and IBD, ET-1 levels correlated positively with CRP level (p = 0.006) and ESR (p = 0.02), and ADMA levels with visual analog scale scores (p = 0.01). Patients with axSpA and IBD had higher serum levels of IL-6 (p = 0.01), IL-18 (p = 0.005), and ADMA (p = 0.01) and lower serum levels of fetuin-A (p = 0.01) than did controls. Conclusions: Patients with axSpA and IBD had higher levels of disease activity, as assessed by ESR and CRP and ET-1 levels, than did patients with axSpA without IBD. Compared to HC, patients with axSpA and IBD had increased IL-18, ADMA levels and decreased fetuin-A level.Keywords
This publication has 18 references indexed in Scilit:
- Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implicationsWorld Journal of Gastroenterology, 2016
- Disease Activity in Ankylosing Spondylitis and Associations to Markers of Vascular Pathology and Traditional Cardiovascular Disease Risk Factors: A Cross-sectional StudyThe Journal of Rheumatology, 2015
- Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysisAnnals of the Rheumatic Diseases, 2015
- Serum IL‐6 and IL‐23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO SyndromeMediators of Inflammation, 2015
- Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASISRheumatology, 2014
- Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: Association with other clinical and laboratory parametersJoint Bone Spine, 2011
- Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2α (8-iso-PGF2α) level in patients with inflammatory bowel diseasesInflammatory Bowel Diseases, 2010
- The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selectionAnnals of the Rheumatic Diseases, 2009
- The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritisAnnals of the Rheumatic Diseases, 2009
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984